AB InBev makes fourth bid for SABMiller
Anheuser-Busch InBev raises its offer to 43.50 pounds per SABMiller share, a 48 percent premium from a month earlier, as it intensifies pursuit of the rival brewer. Fiat Chrysler launches Ferrari IPO to fund a 55 billion expansion plan and 9.8 billion valuation. Dow gains 47.37 points extending a seven session rally. Glencore begins steps to sell two copper mines in Australia and Chile to trim debt.
MENTIONED IN THIS ARTICLE
Anheuser-Busch Inbev
Anheuser-Busch
InBev
Sabmiller
AB InBev
Fiat Chrysler
Ferrari
Wall Street
DOW
Dow Jones
Glencore
Cobar
Australia
Lomas Bay
Chile
EMC Follows Four Horsemen to Dell Buyout Huge $70 billion deal ends EMC independence
EMC, once hailed as a top internet era stock among the Four Horsemen, is set to be acquired by Dell for about 70 billion dollars. The move marks the end of EMC as an independent company and serves as a cautionary tale on chasing hot shares during booms. Oracle stands as the lone horseman outperforming the S&P 500 since 1999, while EMC lags with about 28 percent gain. Cisco and Sun have faded, and the dotcom era hype meets reality.
MENTIONED IN THIS ARTICLE
EMC
Dell
Cisco Systems
Oracle
Sun Microsystems
Four Horsemen
Standard & Poor
Dell's bold path to an EMC tied enterprise titan
Michael Dell reshapes Dell by acquiring EMC for 67 billion, aiming to top HP and IBM in enterprise tech. The strategy centers on data centers, cloud, devices, and the Internet of Things, evolving from a PC maker to a broad tech juggernaut through privateownership, acquisitions, and strategic partnerships with Dropbox, Microsoft, and Google. Dell portrays the move as the culmination of a six-year plan to expand beyond consumer PCs into servers, storage, software, and services.
MENTIONED IN THIS ARTICLE
Michael Dell
Dell
EMC
Hewlett-Packard
IBM
Round Rock
Texas
USA Today
Computer Associates
John Swainson
Marius Haas
Wyse Technology
Sonicwall
Dell Research Division
Dell Ventures
Dell-Emc
Carl Icahn
Fortune
Austin
Dropbox
Microsoft
Google
University of Texas
Lilly halts cholesterol drug evacetrapib derailing study
Eli Lilly stock fell about 8 percent after the company stopped development of evacetrapib in a late-stage trial involving 12,095 patients at 540 sites across 37 countries. The failure to reach the primary endpoint led analysts to reassess the drug’s prospects, though Lilly remains confident in its broader pipeline.
MENTIONED IN THIS ARTICLE
Eli Lilly
Lilly
Food and Drug Administration
David Ricks
Lilly Bio-Medicines
Credit Suisse
Vamil Divan
Divan
Also Mentioned on This Page
Moneyline
DOW Jones Industrial
Marketwatch.com
USA
Northwestern Mutual Planning
M&a
Facebook
Silver Lake Management
MBO
Apple
Netflix
Hewlett- Packard
Broadcom
Ascend Communications
Avago Technologies
itsApp
Sir
Compaq Computer
Lucent Technologies
Dealogic USA Today
San Francisco
SUI Oroctor NO
AFP/GETTY IMAGES
This is just the beginning! Our collection holds over 300 years of history, including rare newspapers, obituaries, marriage records, birth records, and so much more—most of which you won’t find anywhere else!